TARRYTOWN, NY--Regeneron Pharmaceuticals here has named David Valenzuela to the position of vice-president of genomics and bioinformatics. He was previously Regeneron's senior director for genomics and bioinformatics. In addition, the company added the title of chief scientific officer to the position of George Yancopoulos, who remains the company's senior vice-president of research.
Commenting on Valenzuela's promotion, Yancopoulos noted that the bioinformatics executive "is responsible for the identification and cloning of novel genes that serve as targets for drug screens." Yancopoulos continued, "David has made many key discoveries for Regeneron in the last four years, and we believe that in his new position David will continue to make important contributions to the company's drug discovery
programs."
Regeneron focuses on applying molecular and cell biology to the task of drug discovery.